Suppr超能文献

血小板 PAR4 的基因缺失可导致血栓形成减少和止血栓稳定性受损。

Genetic deletion of platelet PAR4 results in reduced thrombosis and impaired hemostatic plug stability.

机构信息

UNC Blood Research Center, Department of Medicine, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, USA.

Department of Biochemistry and Biophysics, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, USA.

出版信息

J Thromb Haemost. 2022 Feb;20(2):422-433. doi: 10.1111/jth.15569. Epub 2021 Nov 10.

Abstract

BACKGROUND

Protease-activated receptor 4 (PAR4) is expressed by a wide variety of cells, including megakaryocytes/platelets, immune cells, cardiomyocytes, and lung epithelial cells. It is the only functional thrombin receptor on murine platelets. A global deficiency of PAR4 is associated with impaired hemostasis and reduced thrombosis.

OBJECTIVE

We aimed to generate a mouse line with a megakaryocyte/platelet-specific deletion of PAR4 (PAR4 ;PF4 ) and use the mouse line to investigate the role of platelet PAR4 in hemostasis and thrombosis in mice.

METHODS

Platelets from PAR4 ;PF4 were characterized in vitro. Arterial and venous thrombosis was analyzed. Hemostatic plug formation was analyzed using a saphenous vein laser injury model in mice with global or megakaryocyte/platelet-specific deletion of PAR4 or wild-type mice treated with thrombin or glycoprotein VI (GPVI) inhibitors.

RESULTS

PAR4 ;PF4 platelets were unresponsive to thrombin or specific PAR4 stimulation but not to other agonists. PAR4 and PAR4 ;PF4 mice both exhibited a similar reduction in arterial thrombosis compared to their respective controls. More importantly, we show for the first time that platelet PAR4 is critical for venous thrombosis in mice. In addition, PAR4 mice and PAR4 ;PF4 mice exhibited a similar impairment in hemostatic plug stability in a saphenous vein laser injury model. Inhibition of thrombin in wild-type mice gave a similar phenotype. Combined PAR4 deficiency on platelets with GPVI inhibition did not impair hemostatic plug formation but further reduced plug stability.

CONCLUSION

We generated a novel PAR4 ;PF4 mouse line. We used this mouse line to show that PAR4 signaling in platelets is critical for arterial and venous thrombosis and hemostatic plug stability.

摘要

背景

蛋白酶激活受体 4(PAR4)表达于多种细胞,包括巨核细胞/血小板、免疫细胞、心肌细胞和肺上皮细胞。它是鼠类血小板上唯一有功能的凝血酶受体。PAR4 整体缺失与止血功能受损和血栓形成减少相关。

目的

我们旨在构建一种巨核细胞/血小板特异性 PAR4 缺失(PAR4 ;PF4 )的小鼠品系,并利用该小鼠品系研究血小板 PAR4 在小鼠止血和血栓形成中的作用。

方法

体外鉴定 PAR4 ;PF4 血小板。分析动脉和静脉血栓形成。利用全 PAR4 或巨核细胞/血小板特异性 PAR4 缺失或野生型小鼠的隐静脉激光损伤模型分析止血栓形成,并用凝血酶或糖蛋白 VI(GPVI)抑制剂处理。

结果

PAR4 ;PF4 血小板对凝血酶或特定 PAR4 刺激无反应,但对其他激动剂有反应。与各自的对照相比,PAR4 和 PAR4 ;PF4 小鼠的动脉血栓形成均减少。更重要的是,我们首次表明血小板 PAR4 对小鼠静脉血栓形成至关重要。此外,在隐静脉激光损伤模型中,PAR4 小鼠和 PAR4 ;PF4 小鼠的止血栓稳定性也出现相似的损伤。在野生型小鼠中抑制凝血酶也会出现类似表型。在血小板上同时缺失 PAR4 并抑制 GPVI 不会影响止血栓形成,但会进一步降低栓稳定性。

结论

我们构建了一种新型的 PAR4 ;PF4 小鼠品系。利用该小鼠品系表明,血小板 PAR4 信号对动脉和静脉血栓形成以及止血栓稳定性至关重要。

相似文献

1
Genetic deletion of platelet PAR4 results in reduced thrombosis and impaired hemostatic plug stability.
J Thromb Haemost. 2022 Feb;20(2):422-433. doi: 10.1111/jth.15569. Epub 2021 Nov 10.
2
Redundancy and interaction of thrombin- and collagen-mediated platelet activation in tail bleeding and carotid thrombosis in mice.
Arterioscler Thromb Vasc Biol. 2014 Dec;34(12):2563-9. doi: 10.1161/ATVBAHA.114.304244. Epub 2014 Oct 2.
3
A mouse model of the protease-activated receptor 4 Pro310Leu variant has reduced platelet reactivity.
J Thromb Haemost. 2024 Jun;22(6):1715-1726. doi: 10.1016/j.jtha.2024.03.004. Epub 2024 Mar 19.
5
Inhibition of protease-activated receptor 4 impairs platelet procoagulant activity during thrombus formation in human blood.
J Thromb Haemost. 2016 Aug;14(8):1642-54. doi: 10.1111/jth.13293. Epub 2016 Jun 22.
6
Platelet Gi protein Gαi2 is an essential mediator of thrombo-inflammatory organ damage in mice.
Proc Natl Acad Sci U S A. 2015 May 19;112(20):6491-6. doi: 10.1073/pnas.1505887112. Epub 2015 May 5.
7
Lipid Receptor GPR31 (G-Protein-Coupled Receptor 31) Regulates Platelet Reactivity and Thrombosis Without Affecting Hemostasis.
Arterioscler Thromb Vasc Biol. 2021 Jan;41(1):e33-e45. doi: 10.1161/ATVBAHA.120.315154. Epub 2020 Dec 3.
9
CLEC-2 Supports Platelet Aggregation in Mouse but not Human Blood at Arterial Shear.
Thromb Haemost. 2022 Dec;122(12):1988-2000. doi: 10.1055/a-1896-6992. Epub 2022 Jul 11.
10
Myosin light chain 6 (Myl6) interacts with kindlin-3 and is required to support integrin αβ activation in platelets in mice.
J Thromb Haemost. 2024 Jul;22(7):2009-2017. doi: 10.1016/j.jtha.2024.01.007. Epub 2024 Jan 22.

引用本文的文献

1
Scoring systems to predict thrombotic complications in solid tumor patients.
Curr Opin Hematol. 2025 May 1;32(3):168-175. doi: 10.1097/MOH.0000000000000862. Epub 2025 Feb 7.
2
The Multifaceted Roles of Thrombomodulin: Anti-coagulation, Anti-inflammation, and Anti-tumor Potential.
Curr Pharm Des. 2025;31(21):1673-1682. doi: 10.2174/0113816128335289241218161938.
3
Mice with reduced protease-activated receptor 4 reactivity show decreased venous thrombosis and platelet procoagulant activity.
J Thromb Haemost. 2025 Apr;23(4):1278-1288. doi: 10.1016/j.jtha.2024.12.031. Epub 2025 Jan 9.
4
Mice with Reduced PAR4 Reactivity show Decreased Venous Thrombosis and Platelet Procoagulant Activity.
bioRxiv. 2024 Oct 17:2024.10.14.617127. doi: 10.1101/2024.10.14.617127.
6
A mouse model of the protease-activated receptor 4 Pro310Leu variant has reduced platelet reactivity.
J Thromb Haemost. 2024 Jun;22(6):1715-1726. doi: 10.1016/j.jtha.2024.03.004. Epub 2024 Mar 19.
7
New Insights in the Pathology of Chronic Thromboembolic Pulmonary Hypertension.
JACC Basic Transl Sci. 2024 Jan 22;9(1):117-119. doi: 10.1016/j.jacbts.2023.11.009. eCollection 2024 Jan.
8
Dual antithrombotic therapy dose-dependently alters hemostatic plug structure and function.
J Thromb Haemost. 2024 Apr;22(4):1016-1023. doi: 10.1016/j.jtha.2023.12.017. Epub 2023 Dec 23.
10
Targeting PAR4 to Reduce Atherosclerosis.
Arterioscler Thromb Vasc Biol. 2023 Nov;43(11):2179-2182. doi: 10.1161/ATVBAHA.123.320046. Epub 2023 Sep 28.

本文引用的文献

1
Platelet Activation and Chemokine Release Are Related to Local Neutrophil-Dominant Inflammation During Hyperacute Human Stroke.
Transl Stroke Res. 2022 Jun;13(3):364-369. doi: 10.1007/s12975-021-00938-w. Epub 2021 Aug 28.
2
Protease-activated receptors: An illustrated review.
Res Pract Thromb Haemost. 2020 Dec 6;5(1):17-26. doi: 10.1002/rth2.12454. eCollection 2021 Jan.
3
Model-dependent contributions of FXII and FXI to venous thrombosis in mice.
J Thromb Haemost. 2020 Nov;18(11):2899-2909. doi: 10.1111/jth.15037. Epub 2020 Aug 28.
4
Loss of Protease-Activated Receptor 4 Prevents Inflammation Resolution and Predisposes the Heart to Cardiac Rupture After Myocardial Infarction.
Circulation. 2020 Aug 25;142(8):758-775. doi: 10.1161/CIRCULATIONAHA.119.044340. Epub 2020 Jun 3.
5
Using PAR4 Inhibition as an Anti-Thrombotic Approach: Why, How, and When?
Int J Mol Sci. 2019 Nov 11;20(22):5629. doi: 10.3390/ijms20225629.
6
Protease-activated receptor 4 protects mice from Coxsackievirus B3 and H1N1 influenza A virus infection.
Cell Immunol. 2019 Oct;344:103949. doi: 10.1016/j.cellimm.2019.103949. Epub 2019 Jul 3.
7
Protease Activated Receptor 4 as a Novel Modulator of Regulatory T Cell Function.
Front Immunol. 2019 Jun 18;10:1311. doi: 10.3389/fimmu.2019.01311. eCollection 2019.
8
Roles of Coagulation Proteases and PARs (Protease-Activated Receptors) in Mouse Models of Inflammatory Diseases.
Arterioscler Thromb Vasc Biol. 2019 Jan;39(1):13-24. doi: 10.1161/ATVBAHA.118.311655.
9
PAR4 (Protease-Activated Receptor 4): PARticularly Important 4 Antiplatelet Therapy.
Arterioscler Thromb Vasc Biol. 2018 Feb;38(2):287-289. doi: 10.1161/ATVBAHA.117.310550.
10
PAR4 (Protease-Activated Receptor 4) Antagonism With BMS-986120 Inhibits Human Ex Vivo Thrombus Formation.
Arterioscler Thromb Vasc Biol. 2018 Feb;38(2):448-456. doi: 10.1161/ATVBAHA.117.310104. Epub 2017 Dec 21.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验